6
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T13112 | Tat-NR2B9c | Tat-NR2Bct,NA-1 | NO Synthase , iGluR |
Tat-NR2B9c (NA-1) is a postsynaptic density-95 (PSD-95) inhibitor with neuroprotective and antiepileptic effects.Tat-NR2B9c inhibits PSD-95d2, PSD-95d1, and PSD-95, which prevents the activation of NMDA-induced NADPH oxi... | |||
T13112L1 | Tat-NR2B9c acetate | Tat-NR2B9c acetate (500992-11-0 Free base),NA-1 acetate | Others |
Tat-NR2B9c acetate (NA-1 acetate) is a postsynaptic density-95 (PSD-95) inhibitor, with EC50 values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c acetate disrupts the PSD-... | |||
T13112L | Tat-NR2B9c TFA | NA-1 (TFA) | Others |
Tat-NR2B9c TFA is a 20-aa peptide, and acts as an inhibitor of postsynaptic density-95 (PSD-95)(EC50 of 6.7 nM for PSD-95d2), and possesses neuroprotective efficacy. | |||
T62921 | EBNA1-IN-SC7 | ||
EBNA1-IN-SC7 (compound SC7) is a selective inhibitor of Epstein-Barr nuclear antigen 1 (EBNA1) that interferes with EBNA1-DNA binding activity (IC50: 23 μM). Barr virus (EBV) related cancers. | |||
T62765 | WRNA10 | ||
WRNA10 is a potent binding agent for HIV-1TAR RNA (IC50: 10 μM, CC50: 40 μM). | |||
T79673 | LUNA18 | Ras | |
LUNA18 is an orally active inhibitor targeting KRAS, exhibiting potent activity with an IC50 value of less than 2 nM against the KRAS G12D-SOS mutation. It is utilized in cancer research [1]. |